Sirolimus in Combination with Tacrolimus in Allogeneic Stem Cell Transplantation—Timing and Conditioning Regimen May Be Crucial  by Wolff, Daniel et al.
LETTER TO THE EDITOR
Biology of Blood and Marrow Transplantation 14:942-943 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1408-0001$32.00/0Sirolimus in Combination
with Tacrolimus in
Allogeneic Stem Cell
Transplantation—Timing
and Conditioning Regimen
May Be Crucial
In a recent issue of Biology of Blood and Bone Marrow
Transplantation, Furlong and colleagues [1] reported
on the results of 2 prospective trials evaluating the
combination of Sirolimus (SIR) with either Cyclospor-
ine (CsA) or Tacrolimus (TAC) and additional
methotrexate (MTX) for prophylaxis of acute graft-
versus-host disease (aGVHD) after allogeneic stem
cell transplantation from unrelated donors (URD). In
contrast to previous publications by Antin and col-
leagues [2,3], both studies presented by Furlong et al.
observed a high rate of toxicity and no reduction in
aGVHD, which led to premature termination of
both studies because of lack of efficacy. In this context
3 additional aspects need to be discussed.
First, in the Furlong study, the immunosuppres-
sion combining CsA with SIR started on day 21,
whereas in the phase II studies published by Antin
et al. [2] immunosuppression started on day 23. Be-
cause SIR has a potential inhibitory effect on function
of dendritic cells, the delayed start of immunosuppres-
sion may have contributed to the higher rate of
aGVHD [4-6]. Moreover, in vitro data and compara-
tive clinical studies in renal transplantation showed
a higher efficacy and potentially improved toxicity
profile of the combination of TAC and SIR compared
to CsA and SIR [7-9]. Another potential reason for
a higher failure rate may have been the combination
of a conditioning regimen containing busulfan (Bu)
with an immunosuppression regimen containing
TAC and SIR. In prior studies, Bu as well as cyclophos-
phamide (Cy) have been associated with increased tox-
icity to endothelial cells via decreased glutathione
levels in hepatocytes and subsequent VOD, which po-
tentially overlaps with decreased glutathione synthesis
caused by SIR as shown in a rat model [10-12]. This is
supported by a report of Platzbecker et al. [13], who
observed an increased rate of VOD after Busulfan-
based conditioning regimen and posttransplantation
immunosuppression with Everolimus and TAC. Fur-942thermore, the increased endothelial toxicity of the
combination of SIR and TAC is reflected by an in-
creased rate of thrombotic microangiopathy, which
may have led to dose reduction of the immunosuppres-
sion and a subsequent higher rate of GVHD [14].
The influence of the conditioning regimen is sup-
ported by the results of a retrospective analysis of 8
patients receiving SIR in combination with TAC and
MTX after allogeneic peripheral stem cell transplanta-
tion at our institution. All 8 patients had high risk fea-
tures (acute myelogenous leukemia [AML] first partial
remission [PR; n 5 2], refractory AML [n 5 2], sec-
ondary myelodysplastic syndromes [MDS] RAEB II
[n5 1], CML second AP [n5 1], non-Hodgkin Lym-
phoma [NHL] second PR [n5 1], and refractory CLL
[n 5 1]). Donor types were HLA mismatched unre-
lated n 5 4 (8 of 10 [n 5 3], 9 of 10 [n 5 1], matched
unrelated (10 of 10 [n5 2]), and matched related (n5
2). The median age of patients was 59 years (52-65
years). The conditioning regimen consisted of Fludar-
abine 5  30 mg/m2 day –7 to day –3 and Treosulfan
either 5  10 g/m2 day –7 to day –3 (n 5 7) or 3 
14 g/m2 day –7 to day –5 (n 5 1). GVHD prophylaxis
consisted of SIR starting on day –2, with a loading dose
of 12 mg followed by 4 mg/day and dose adjustment
according to plasma levels 5-15 ng/mL. TAC was ad-
ministered intravenously as continuous infusion be-
ginning on day –2 with an initial dose of 0.03 mg/kg
bodyweight and subsequent dose adjustment for
plasma levels 5-15 ng/mL. Additional MTX was given
with a dose of 5 mg/m2 on days 1, 3, 6, and 11 after
transplantation to recipients of unrelated donors.
With a median follow-up of 220 days (158-356 days)
no treatment-related mortality (TRM) was observed.
aGVHD was observed in 2 patients after stop of im-
munosuppression (grade II [n 5 1], grade III [n 5
1]), with an onset on days 101 and 172. Moderate ste-
roid-responsive chronic GVHD (cGVHD) occurred
in 2 additional patients after the stop of immunosup-
pression. Two patients with refractory AML before
transplantation died because of relapse of AML on
days 114 and 180. A relevant side effect because of con-
ditioning-related toxicity of Treosulfan was a transient
elevation of liver enzymes. Mild microangiopathy as-
sociated solely with mild hemolysis was observed in 3
of 8 patients, which resolved after dose reduction of
SIR. Although VOD of the liver was not observed,
mild to moderate nephrotoxicity mainly in association
with infectious complications was observed in 4
patients, which resolved after dose reduction of TAC.
Letter to the Editor 943Although the low number of patients does not
permit any statistical conclusion, the results are in
line with the results published by Antin et al. [2] in
terms of efficacy and toxicity despite the inclusion of
3 patients with unrelated donors differing in 2HLA al-
leles with the recipient. Moreover, the use of SIR after
conditioning with Treosulfan was not associated with
VOD. The discrepant results reported by Furlong
and Antin and their colleagues demonstrate the urgent
need for comparison of SIR-based immunosuppressive
regimens with the current standard based on the com-
bination of a calcineurin inhibitor and MTX in a ran-
domized trial, which is currently recruiting under the
sponsorship of the National Cancer Institute (BMT
CTN 0402), but timing and conditioning regimen
may be of additional relevance.
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